Anti-Inflammatory Peptides: How Peptides Interact with Inflammatory Pathways

Key Takeaways

• Compounds covered: BPC-157, thymosin alpha-1, KPV (Lys-Pro-Val), LL-37 (cathelicidin), GHK-Cu, TB-500 (thymosin beta-4 fragment)
• Goal area: Systemic and local inflammation reduction — including tissue-level, gut, immune-system, and chronic inflammatory contexts
• Evidence range: Ranges from completed human clinical trials in specific disease populations (thymosin alpha-1) to extensive preclinical animal models (BPC-157, TB-500) to cell culture and animal inflammation data (KPV, LL-37, GHK-Cu)
• Regulatory range: Thymosin alpha-1 is not FDA-approved and is not on the FDA 503A Category 1 permitted bulk drug substances list (PCAC declined to recommend it for Category 1); BPC-157 was removed from the FDA 503A Category 2 bulk drug substances list on April 22, 2026; removal is not an FDA approval, BPC-157 has not been placed on Category 1, and 503A compounding eligibility under the bulks pathway remains unsettled pending PCAC review; TB-500 was removed alongside BPC-157 on April 22, 2026 under the same framework and is not available through licensed US prescribers under any affirmative FDA pathway; KPV is not on FDA 503A Category 1, is not a component of any FDA-approved drug, and has no applicable USP/NF monograph — failing all three § 353a(b)(1)(A) criteria for lawful 503A bulk compounding; LL-37 is not FDA-approved and has no affirmative 503A compounding pathway; topical GHK-Cu is regulated as a cosmetic ingredient under FDCA § 201(i); injectable GHK-Cu is not FDA-approved and is not on the FDA 503A Category 1 list
• Key biomarkers for inflammation: hs-CRP, IL-6 (where commercially available), neutrophil-to-lymphocyte ratio, CBC differential, comprehensive metabolic panel (liver/kidney baseline)
• As of April 2026: No peptide in this article is FDA-approved for any inflammatory indication. Thymosin alpha-1 has the most human evidence but in specific disease populations, not general inflammation.
• Bottom line: Evidence quality varies substantially by compound; thymosin alpha-1 has human trial data; BPC-157 has extensive preclinical evidence; KPV and LL-37 are primarily cell culture and animal data.

Low-grade chronic inflammation is increasingly recognized as a contributor to many conditions associated with aging and lifestyle — from joint degeneration and cardiovascular risk to metabolic dysfunction and impaired tissue repair. Pawar, writing in Explore in 2026, characterized chronic low-grade inflammation in young adults as a contributor to long-term outcomes. Peptides studied for anti-inflammatory effects interact with this biology through distinct mechanisms — some modulating the immune system systemically, others acting on specific tissue-level inflammatory pathways. The range of evidence quality across these compounds is as wide as the range of mechanisms.

Understanding Inflammation: The Biology

Inflammation is a necessary biological response. Acute inflammation — the swelling, redness, and heat that follow tissue injury or infection — is the body's mechanism for clearing damage, recruiting repair cells, and initiating healing. The problem is not acute inflammation. It is chronic, low-grade inflammatory signaling that persists without resolution, driven by metabolic dysfunction, accumulated oxidative stress, gut barrier disruption, or persistent immune activation.

At the molecular level, two pathways dominate inflammatory signaling. NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a central transcription factor of inflammation: its activation drives production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. NLRP3 inflammasome activation is a second critical pathway, particularly relevant to metabolic and age-related inflammation. Both pathways can be driven by diverse upstream inputs — from bacterial products and tissue damage signals to oxidized lipids and elevated blood glucose.

The immune system's role in inflammation is bidirectional. Innate immune cells (neutrophils, macrophages, dendritic cells) initiate and amplify inflammatory responses; adaptive immune cells (T-cells, B-cells) can either resolve inflammation or perpetuate it depending on the balance of regulatory and effector activity. Thymic-derived regulatory T-cells and the cytokine environment they operate in are the proximate regulators of whether an immune response resolves or persists. This is why compounds targeting the immune system's regulatory apparatus — like thymosin alpha-1 — have a fundamentally different mechanism than compounds targeting local tissue inflammation.

Gut barrier integrity intersects with systemic inflammation through the translocation of microbial products into the bloodstream: disrupted tight junctions allow lipopolysaccharide (LPS) and other bacterial fragments to activate systemic innate immune responses, driving chronic low-grade inflammation well beyond the gut. This pathway connects intestinal peptide research to systemic inflammatory endpoints.

Peptides Studied for Inflammation: A Quick Comparison

The following peptides have published evidence relevant to inflammation. Listed by the weight of human evidence, from most-studied to least.

• Compound: Thymosin alpha-1
  Mechanism for inflammation: Systemic immune modulation via dendritic cell regulation, T-cell maturation support, and cytokine balance — described as a "regulator of regulators" of immune homeostasis
  Evidence: Completed human clinical trials in infectious disease (HBV, HCV, sepsis) and adjuvant oncology contexts; immune-modulatory effects in human subjects established
  FDA status: Not FDA-approved in the US for any indication; not on the FDA 503A Category 1 permitted bulk drug substances list (PCAC declined to recommend it for Category 1); historically compounded in the US under varying interpretations of 503A bulk sourcing rules, activity that remains subject to ongoing FDA enforcement attention
  SP availability: Not currently available through Superpower
  Route: Subcutaneous injection
• Compound: BPC-157
  Mechanism for inflammation: NO-system cytoprotection; tissue-specific anti-inflammatory effects; VEGFR2-mediated angiogenesis supporting repair; neurotransmitter modulation affecting neuroinflammatory pathways
  Evidence: Extensive preclinical animal studies across GI, musculoskeletal, and vascular contexts; one human IV safety pilot (2025); no completed human inflammation RCT
  FDA status: Not FDA-approved. Removed from the FDA 503A Category 2 bulk drug substances list on April 22, 2026; removal is not approval, BPC-157 has not been placed on Category 1, and 503A compounding eligibility under the bulks pathway is unsettled pending PCAC review
  SP availability: Not currently available through Superpower
  Route: Subcutaneous or intramuscular injection in animal studies; oral also studied
• Compound: GHK-Cu (glycyl-L-histidyl-L-lysine copper complex)
  Mechanism for inflammation: Genomic downregulation of inflammatory gene clusters; copper-mediated reduction of oxidative stress; antifibrotic signaling; angiogenesis supporting tissue repair
  Evidence: In vitro gene expression studies; animal models in pulmonary fibrosis and oxidative damage; no human RCT for anti-inflammatory effects
  FDA status: Topical: regulated as a cosmetic ingredient under FDCA § 201(i); injectable: not FDA-approved and not on the FDA 503A Category 1 permitted bulk drug substances list — some pharmacies prepare it under varying interpretations of 503A bulk sourcing rules, activity subject to ongoing FDA enforcement attention
  SP availability: Not currently available through Superpower
  Route: Topical; subcutaneous injection (compounded)
• Compound: TB-500 (thymosin beta-4 synthetic fragment)
  Mechanism for inflammation: Actin sequestration reducing inflammatory myofibroblast activity; anti-fibrotic and angiogenic effects; tissue protection in inflammatory injury models
  Evidence: Animal models of cardiac, musculoskeletal, and tissue injury with inflammatory components; no human RCT
  FDA status: Not FDA-approved. Removed from the FDA 503A Category 2 bulk drug substances list on April 22, 2026 alongside BPC-157; removal is not approval, TB-500 has not been placed on Category 1, and 503A compounding eligibility under the bulks pathway is unsettled. Not available through licensed US prescribers under any affirmative FDA pathway
  SP availability: Not currently available through Superpower
  Route: Subcutaneous injection in research context
• Compound: KPV (Lys-Pro-Val)
  Mechanism for inflammation: MC3R agonism suppressing NF-kB-driven inflammatory cascades in intestinal epithelial cells; uptake via PepT1 transporter in gut
  Evidence: Animal colitis models; in vitro intestinal inflammation studies; no human clinical data
  FDA status: Not FDA-approved; not on 503A Category 1 list; research-only
  SP availability: Not currently available through Superpower
  Route: Oral or local gut delivery in animal models
• Compound: LL-37 (cathelicidin)
  Mechanism for inflammation: Innate immune modulation; wound healing promotion via TFEB-dependent autophagy regulation; antimicrobial activity reducing infection-driven inflammation
  Evidence: Cell culture and animal wound healing models; no completed human inflammation RCT
  FDA status: Not FDA-approved; no affirmative 503A compounding pathway; not available through licensed US prescribers under any affirmative FDA pathway
  SP availability: Not currently available through Superpower
  Route: Topical or local delivery studied in preclinical models

Compounds listed as research-only or experimental have not been evaluated in the clinical trials required for FDA approval. Their inclusion here is for educational context only.

Peptides Studied for Inflammation: Individual Profiles

Each compound targets inflammation through a mechanistically distinct pathway. They are not interchangeable. Evidence quality and regulatory access differ significantly across this group.

Thymosin alpha-1

Thymosin alpha-1 is a 28-amino-acid peptide naturally secreted by thymic epithelial cells. It is not FDA-approved for any indication in the US, but it has the most human clinical trial data of any compound in this article — tested in clinical trials for hepatitis B, hepatitis C, sepsis, and as an adjuvant in cancer therapy. It is not on the FDA 503A Category 1 permitted bulk drug substances list, and the FDA Pharmacy Compounding Advisory Committee (PCAC) declined to recommend it for Category 1 inclusion; some pharmacies have historically compounded it under varying interpretations of 503A bulk sourcing rules, but this activity is the subject of ongoing FDA enforcement attention.

The proposed mechanism for inflammation involves thymosin alpha-1's role in immune homeostasis at multiple levels. Pierluigi and colleagues, writing in the Annals of the New York Academy of Sciences in 2010, characterized thymosin alpha-1 as a "regulator of regulators" in immune homeostasis — modulating both innate and adaptive immune responses rather than simply suppressing or activating them. Romani and colleagues, writing in Blood in 2006, demonstrated that thymosin alpha-1 activates dendritic cell tryptophan catabolism, describing a mechanistic pathway relevant to inflammatory and tolerogenic immune responses. Serafino and colleagues, writing in the Annals of the New York Academy of Sciences in 2012, documented thymosin alpha-1 as a stimulatory agent of innate immunity — establishing its dual role as both pro-immune and regulatory, depending on the biological context.

For human evidence, Dinetz and colleagues, writing in Alternative Therapies in Health and Medicine in 2024, reviewed thymosin alpha-1 across human trials, documenting consistent immune-modulatory effects in infectious disease and cancer populations with a favorable safety profile. The human evidence is in specific disease contexts — not general chronic inflammation in otherwise healthy individuals. Off-label use of thymosin alpha-1 for general inflammation has not been evaluated in adequate clinical trials. Its use for inflammatory indications outside the studied populations has not been approved by the FDA.

[Human clinical trial data in specific disease populations; off-label use for general inflammation not supported by RCT evidence]

Not FDA-approved in the US. Not on the FDA 503A Category 1 permitted bulk drug substances list; PCAC declined to recommend it for Category 1 inclusion; historical compounding activity is subject to ongoing FDA enforcement attention. Not currently available through Superpower.

BPC-157

BPC-157 is a synthetic 15-amino-acid pentadecapeptide studied extensively in animal models for both local and systemic anti-inflammatory effects. It is not FDA-approved. As of April 22, 2026, the FDA removed BPC-157 from the Category 2 bulk drug substances list. This removal is not an FDA approval, BPC-157 has not been placed on Category 1, and 503A compounding eligibility under the bulks pathway remains unsettled pending PCAC review.

The proposed anti-inflammatory mechanism centers on the nitric oxide system and cytoprotection. Jozwiak and colleagues, writing in Pharmaceuticals in 2025, published a comprehensive review synthesizing BPC-157's multifunctional anti-inflammatory mechanisms across organ systems, representing the most current evidence synthesis. Yuan and colleagues, writing in the International Journal of Molecular Sciences in 2026, reviewed BPC-157 in tissue repair. Staresinic and colleagues (Sikiric group), writing in Biomedicines in 2022, documented BPC-157's anti-inflammatory effects in cardiac and smooth muscle, demonstrating its mechanistic reach beyond the GI tract. The same group, writing in Inflammopharmacology in 2024, described BPC-157's cytoprotective mechanisms in multiorgan inflammation. Sikiric and colleagues, writing in Inflammopharmacology in 2006, documented BPC-157's anti-inflammatory and vascular effects in IBD. For pain alongside inflammation, Jung and colleagues, writing in the Journal of Dental Anesthesia and Pain Medicine in 2022, demonstrated BPC-157's anti-nociceptive effects in incisional pain.

The balanced framing from McGuire and colleagues in their 2025 Current Reviews in Musculoskeletal Medicine narrative review applies here: BPC-157 shows regenerative potential with unresolved safety concerns, and the absence of human RCT data means clinical conclusions for human inflammatory applications cannot be drawn.

[Extensive animal study evidence across multiple tissue types; one human IV safety pilot (2025); no completed human inflammation RCT]

Not available through Superpower. Not available through licensed US prescribers under any affirmative FDA pathway; 503A compounding eligibility under the bulks pathway is unsettled following the April 22, 2026 removal from Category 2.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex)

GHK-Cu is a naturally occurring human tripeptide with copper-mediated anti-inflammatory and tissue-protective effects. As a topical cosmetic ingredient under FDCA § 201(i) it is OTC (when sold as a topical cosmetic, GHK-Cu may not carry anti-inflammatory or disease-modifying claims; anti-inflammatory discussion in this article refers to the research context only); injectable GHK-Cu is not FDA-approved, is not on the FDA 503A Category 1 permitted bulk drug substances list, and is not a component of any FDA-approved drug — some compounding pharmacies prepare it under varying interpretations of 503A bulk sourcing rules, and this activity is the subject of ongoing FDA enforcement attention.

The primary evidence for GHK-Cu's anti-inflammatory activity comes from genomic studies. Pickart and colleagues, writing in BioMed Research International in 2014, demonstrated that GHK-Cu shifted gene expression in cell models, including the simultaneous downregulation of hundreds of inflammation-associated gene clusters — though this is genomic data from cell models, not human clinical outcomes. Pickart's foundational 2008 paper in the Journal of Biomaterials Science established GHK-Cu's role in tissue remodeling. Ma and colleagues, writing in Life Sciences in 2020, showed GHK-Cu exerts anti-inflammatory effects in pulmonary fibrosis — supporting its proposed mechanism in preclinical models of oxidative-stress-driven inflammation. Zhang and colleagues, writing in Frontiers in Molecular Biosciences in 2022, demonstrated GHK-Cu's attenuation of oxidative stress inflammation in a smoke-induced emphysema model.

[In vitro genomic data; animal inflammation models; no human RCT for injectable GHK-Cu in inflammatory applications]

Topical GHK-Cu: OTC cosmetic under FDCA § 201(i), no drug claims. Injectable GHK-Cu: not FDA-approved and not on the FDA 503A Category 1 permitted bulk drug substances list; some compounding pharmacies prepare it under varying interpretations of 503A bulk sourcing rules, activity subject to ongoing FDA enforcement attention. Not currently available through Superpower.

TB-500 (thymosin beta-4 synthetic fragment)

TB-500 is a synthetic thymosin beta-4 fragment studied for its anti-fibrotic and tissue-protective effects in inflammatory injury models. Its primary anti-inflammatory mechanism in preclinical data involves reducing myofibroblast activation (the cell type responsible for scarring in inflammatory resolution) and supporting angiogenesis in inflamed tissue. Bjorklund and colleagues, writing in Current Medicinal Chemistry in 2020, reviewed thymosin beta-4 tissue repair. Dube and colleagues, writing in Expert Opinion on Biological Therapy in 2018, reviewed thymosin beta-4's roles in vascular development and repair including its anti-inflammatory actions.

[Animal inflammation and tissue injury models; no human RCT]

Not FDA-approved. Removed from FDA 503A Category 2 on April 22, 2026 alongside BPC-157; removal is not approval, and TB-500 has not been placed on Category 1. 503A compounding eligibility under the bulks pathway is unsettled. Not available through licensed US prescribers under any affirmative FDA pathway. Prohibited under the 2026 WADA Prohibited List.

KPV (Lys-Pro-Val)

KPV is a C-terminal tripeptide fragment of alpha-MSH that suppresses NF-kB-driven inflammatory signaling through MC3R agonism, with evidence concentrated in gut inflammation models. Land, writing in the International Journal of Physiology, Pathophysiology and Pharmacology in 2012, investigated KPV inhibition of systemic inflammation via MC3R agonism. Bohm and colleagues, writing in Experimental Dermatology in 2019, reviewed melanocortin peptides for wound healing with anti-inflammatory potential. Its evidence is preclinical and focused on intestinal inflammation; it is research-only with no human data.

[Animal and in vitro data; no human clinical data]

Not FDA-approved; no affirmative 503A compounding pathway. Not available through licensed US prescribers under any affirmative FDA pathway. Not available through Superpower.

LL-37 (cathelicidin)

LL-37 is a 37-amino-acid cathelicidin-derived antimicrobial peptide produced by human immune cells and epithelial surfaces. Its anti-inflammatory relevance comes from its role in innate immune modulation — it acts at the interface of infection-driven inflammation and tissue repair. Xi and colleagues, writing in Peptides in 2024, demonstrated LL-37 promotes wound healing in diabetic mice via TFEB-dependent autophagy regulation, a mechanism relevant to inflammation resolution in impaired healing contexts. Its evidence is primarily in cell culture and animal models focused on wound healing and infection-driven inflammation rather than systemic anti-inflammatory applications.

[Cell culture and animal wound healing models; no human inflammation RCT]

Not FDA-approved; no affirmative 503A compounding pathway. Not available through licensed US prescribers under any affirmative FDA pathway. Not available through Superpower.

Regulatory Status at a Glance

As of April 2026, the compounds discussed in this article carry the following regulatory statuses:

• Thymosin alpha-1: Not FDA-approved for any indication in the US. Not on the FDA 503A Category 1 permitted bulk drug substances list; the FDA Pharmacy Compounding Advisory Committee (PCAC) declined to recommend it for Category 1 inclusion. Historical compounding activity in the US is subject to ongoing FDA enforcement attention. Not prescribed, compounded, or dispensed through Superpower.
• BPC-157: Not FDA-approved for any indication. Removed from the FDA 503A Category 2 bulk drug substances list on April 22, 2026; removal is not approval, BPC-157 has not been placed on Category 1, and 503A compounding eligibility under the bulks pathway remains unsettled pending PCAC review.
• GHK-Cu (topical): Regulated as a cosmetic ingredient; not evaluated to diagnose, treat, cure, or prevent any disease.
• GHK-Cu (injectable): Not FDA-approved and not on the FDA 503A Category 1 permitted bulk drug substances list. Some compounding pharmacies prepare it under varying interpretations of 503A bulk sourcing rules; this activity is subject to ongoing FDA enforcement attention. Not dispensed through Superpower.
• TB-500: Not FDA-approved for any indication. Removed from FDA 503A Category 2 on April 22, 2026 alongside BPC-157; removal is not approval, and TB-500 has not been placed on Category 1. 503A compounding eligibility under the bulks pathway is unsettled. Not available through licensed US prescribers under any affirmative FDA pathway. Prohibited under the 2026 WADA Prohibited List (S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics).
• KPV: Not FDA-approved. Not on the FDA 503A Category 1 permitted bulk drug substances list, not a component of any FDA-approved drug, and no applicable USP/NF monograph — failing all three § 353a(b)(1)(A) bulk substance criteria. No affirmative 503A compounding pathway has been established. Not available through licensed US prescribers under any affirmative FDA pathway.
• LL-37: Not FDA-approved for any indication. No affirmative 503A compounding pathway. Not available through licensed US prescribers under any affirmative FDA pathway.

Compounds listed as research-only or experimental have no affirmative 503A compounding pathway and are not available through licensed US prescribers under any affirmative FDA pathway. Their presence in this article is for educational context only.

Considerations When Comparing Anti-Inflammatory Peptides

Direct comparison between these compounds is not supported by their evidence bases. They have been studied in different inflammatory contexts, different disease populations, different animal models, and at different doses. Thymosin alpha-1's human evidence is in infectious and oncological contexts; BPC-157's evidence is across tissue-specific injury models; GHK-Cu's evidence is in cell culture genomics and animal oxidative damage models.

Systemic vs. local inflammation: Thymosin alpha-1 acts on the immune system's regulatory machinery at a systemic level. BPC-157's anti-inflammatory effects are primarily observed in the context of specific tissue injury — they are local and cytoprotective rather than broadly immunosuppressive. KPV's effects are localized to gut epithelial cells. GHK-Cu's genomic effects suggest systemic reach but this has not been confirmed in human trials. Matching a compound to your inflammation pattern requires distinguishing systemic from local drivers.

Inflammatory biomarker profile: Elevated hs-CRP and IL-6 signal systemic inflammatory activity. A provider evaluating the inflammatory context will want to understand what is driving the elevation — metabolic dysfunction, gut permeability, chronic infection, autoimmune activity — before considering any compound or approach. The mechanism of the proposed compound should match the mechanism of the inflammatory driver.

Evidence level: The range from thymosin alpha-1 (human trials) to LL-37 (cell culture) is substantial. A provider will weight evidence quality alongside mechanistic relevance when evaluating options.

Regulatory access: As of April 22, 2026, neither thymosin alpha-1 nor injectable GHK-Cu is on the FDA 503A Category 1 permitted bulk drug substances list; historical compounding activity for these substances is the subject of ongoing FDA enforcement attention. BPC-157 and TB-500 were removed from Category 2 on April 22, 2026 but have not been placed on Category 1; 503A compounding eligibility is unsettled, and neither is available through licensed US prescribers under any affirmative FDA pathway. KPV and LL-37 fail all three § 353a bulk substance criteria and are not available through licensed US prescribers under any affirmative FDA pathway.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

Safety profiles vary significantly across this group. Thymosin alpha-1 has the most documented human safety data from clinical trials in disease populations — adverse effects were minimal in the reviewed studies. BPC-157's human safety data is limited to one IV pilot study. The remaining compounds — KPV, LL-37, and TB-500 — have no adequate human safety characterization.

Contraindications that apply broadly to anti-inflammatory peptide therapy:

• Active autoimmune conditions — immune-modulating compounds require careful provider evaluation; thymosin alpha-1's immune-modulating activity may interact with baseline immune status in ways that require provider evaluation before use in autoimmune conditions
• Active infection — some immune-modulating compounds may alter infectious disease course; provider evaluation is required
• Pregnancy or breastfeeding — reproductive safety data does not exist for any compound in this article beyond thymosin alpha-1, where data is limited
• Active hormone-sensitive malignancy — angiogenic and immune-modulatory compounds carry theoretical concerns in malignant tissue
• Competitive athletes subject to anti-doping rules — TB-500 (thymosin beta-4 fragment) is prohibited under the 2026 WADA Prohibited List
• Products from unregulated sources — injectable products sold outside licensed pharmacy channels carry contamination and dosing risks

For compound-specific safety profiles, consult individual compound literature and a qualified healthcare provider.

Baseline Biomarkers Relevant to Inflammation Evaluation

If an emerging research compound is being discussed with a qualified specialist, baseline biomarker testing establishes the inflammatory context before any intervention. Without objective baseline values, changes during any protocol have no reference point for interpretation.

• hs-CRP (high-sensitivity C-reactive protein): The primary blood biomarker for systemic inflammatory burden. A baseline hs-CRP value establishes the starting inflammatory level and provides the reference needed to assess whether any intervention is producing measurable change. Superpower's guide to hs-CRP and long-term health covers the clinical significance of this marker in detail.
• Neutrophil-to-lymphocyte ratio (NLR): A simple CBC-derived inflammatory index. An elevated NLR reflects innate immune activation and is a useful complement to hs-CRP for characterizing the immune context of chronic inflammation.
• ALT (alanine aminotransferase): Liver enzyme safety baseline for any injectable compound. A pre-treatment ALT value identifies pre-existing hepatic enzyme elevation that would confound interpretation of changes during any injectable protocol.
• eGFR (estimated glomerular filtration rate): Kidney function baseline. An eGFR value is standard pre-treatment assessment for any injectable compound — renal clearance affects pharmacokinetics.
• Fasting glucose and HbA1c: Metabolic dysregulation is a major driver of chronic low-grade inflammation. A fasting glucose and HbA1c establish whether metabolic contributors are present — context that matters for interpreting what is driving the inflammatory signal and which mechanism-based approach might be most relevant.
• CBC with differential: Provides baseline white blood cell differential counts — relevant for immune-modulating compounds like thymosin alpha-1 where immune cell composition is part of the biological picture.

Testing through the inflammation and muscle recovery biomarker guide covers the inflammatory markers most relevant to this assessment. These values provide the objective context that transforms "my inflammation seems high" into a characterization a provider can act on.

How to Access These Peptides Safely

Neither thymosin alpha-1 nor injectable GHK-Cu is on the FDA 503A Category 1 permitted bulk drug substances list; historical compounding activity for these substances is the subject of ongoing FDA enforcement attention. BPC-157 was removed from FDA Category 2 on April 22, 2026 but has not been placed on Category 1; 503A compounding eligibility under the bulks pathway is unsettled pending PCAC review, and BPC-157 is not available through licensed US prescribers under any affirmative FDA pathway. KPV, LL-37, and TB-500 are not available by prescription in the US.

For anyone with persistent elevated inflammatory markers, the appropriate starting point is clinical evaluation: a primary care physician, rheumatologist, or internist can evaluate the underlying drivers of inflammation — metabolic, autoimmune, infectious, or lifestyle-related — and recommend evidence-based approaches for the specific context. Elevated hs-CRP is a finding that warrants investigation before any compound is considered, because the interventions that address metabolic-driven inflammation differ substantially from those that address immune-dysregulation-driven inflammation.

Products sold online as injectable anti-inflammatory peptides operate outside FDA manufacturing oversight. The absence of regulated manufacturing means identity, purity, and dosing cannot be assumed. Clinical evaluation before purchasing anything is the minimum prudent step.

Understanding Your Baseline

With multiple compounds proposed for inflammation — each operating through a distinct mechanism, each with a different evidence tier — the most useful starting point is knowing what is actually elevated and why. An hs-CRP measurement, a metabolic panel, and an immune cell differential are objective data that make any subsequent clinical conversation specific rather than speculative.

That principle is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to a lifestyle-first approach, a compounded formulation, or further diagnostic investigation, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

Thymosin alpha-1 is not approved by the FDA for any indication in the United States. It is not on the FDA 503A Category 1 permitted bulk drug substances list. The FDA Pharmacy Compounding Advisory Committee (PCAC) declined to recommend it for Category 1 inclusion. Historical US compounding activity for thymosin alpha-1 is the subject of ongoing FDA enforcement attention. All uses discussed in this article are investigational in the US — thymosin alpha-1 is not FDA-approved for any indication. Its safety and efficacy for inflammatory indications in healthy individuals have not been established through adequate and well-controlled clinical trials. Thymosin alpha-1 is not prescribed, compounded, or dispensed through Superpower.

BPC-157 is not approved by the FDA for any medical use. Research has been limited primarily to laboratory and animal studies, with minimal human clinical trial data. Safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. BPC-157 had been on FDA's 503A Category 2 bulk drug substances list (substances the FDA identified as presenting potential safety concerns, rendering them ineligible for the 503A bulks list pending further evaluation). On April 22, 2026, the FDA removed BPC-157 from Category 2. This removal is not an FDA approval, BPC-157 has not been placed on Category 1, and 503A compounding eligibility under the bulks pathway is unsettled pending continued PCAC review. BPC-157 is not prescribed, compounded, or dispensed through Superpower.

GHK-Cu (topical): Regulated as a cosmetic ingredient under FDCA § 201(i). Not evaluated or approved to diagnose, treat, cure, or prevent disease. GHK-Cu (injectable): Not FDA-approved for any indication. Not on the FDA 503A Category 1 permitted bulk drug substances list, not a component of any FDA-approved drug, and has no applicable USP/NF monograph. Some compounding pharmacies prepare it under varying interpretations of 503A bulk sourcing rules; this activity is the subject of ongoing FDA enforcement attention. Not currently prescribed, compounded, or dispensed through Superpower.

TB-500 (synthetic thymosin beta-4 fragment) is not approved by the FDA for any medical use. Research is limited to laboratory and animal studies. Safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. TB-500 was removed from the FDA's 503A Category 2 bulk drug substances list on April 22, 2026 alongside BPC-157; removal is not approval, TB-500 has not been placed on Category 1, and 503A compounding eligibility under the bulks pathway is unsettled. TB-500 is not available through licensed US prescribers under any affirmative FDA pathway. Under the 2026 WADA Prohibited List, thymosin beta-4 and its fragments are prohibited substances in sport (S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). Not prescribed, compounded, or dispensed through Superpower.

KPV (Lys-Pro-Val) is not approved by the FDA for any medical use. It is not on the FDA 503A Category 1 permitted bulk drug substances list, is not a component of any FDA-approved drug, and has no applicable USP/NF monograph — failing all three statutory criteria for lawful 503A bulk compounding under 21 U.S.C. § 353a. No affirmative 503A compounding pathway has been established. Research is limited to laboratory and animal studies with no human clinical data. Not available through licensed US prescribers under any affirmative FDA pathway. Not prescribed, compounded, or dispensed through Superpower.

LL-37 (cathelicidin) is not approved by the FDA for any medical use. Research is limited to cell culture and animal models. Safety, efficacy, and long-term effects in humans have not been established. No affirmative 503A compounding pathway. Not available through licensed US prescribers under any affirmative FDA pathway. Not prescribed, compounded, or dispensed through Superpower.

This content is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any compound. Individual health conditions, medications, and organ function affect both suitability and response.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.